A comprehensive review of hydroxyurea for ß-haemoglobinopathies: the role revisited during COVID-19 pandemic.

Yasara, Nirmani; Premawardhena, Anuja; Mettananda, Sachith

Yasara, Nirmani; Premawardhena, Anuja; Mettananda, Sachith.

Affiliation

Yasara N; Department of Paediatrics, Faculty of Medicine, University of Kelaniya, Thalagolla Road, Ragama, 11010, Sri Lanka.
Premawardhena A; Department of Medicine, Faculty of Medicine, University of Kelaniya, Ragama, Sri Lanka.
Mettananda S; Colombo North Teaching Hospital, Ragama, Sri Lanka.

Orphanet J Rare Dis ; 16(1): 114, 2021 03 01.

Article in En | MEDLINE | ID: mdl-33648529

Subject(s)

COVID-19 Drug Treatment; Hemoglobinopathies/drug therapy; Hydroxyurea/therapeutic use; Bloodless Medical and Surgical Procedures; Enzyme Inhibitors/therapeutic use; Humans; Ribonucleoside Diphosphate Reductase/antagonists & inhibitors

Key words

Blood transfusion; COVID-19; Haemoglobinopathies; Hydroxyurea; Ribonucleoside diphosphate reductase; Sickle cell disease; Thalassaemia; Î³-Globin induction

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: COVID-19 Drug Treatment / Hemoglobinopathies / Hydroxyurea Type of study: Clinical_trials Limits: Humans Language: En Journal: Orphanet J Rare Dis Journal subject: MEDICINA Year: 2021 Type: Article Affiliation country: Sri Lanka

Fulltext

XML

PubMed Links

Search on Google